# Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

> **NCT06996093** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 2508 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
- **DRUG:** aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor

## Key facts

- **NCT ID:** NCT06996093
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2030-06-01
- **Final completion:** 2034-06-01
- **Target enrollment:** 2508 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06996093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06996093, "Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06996093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*